Grants per year
Personal profile
Certifications and Licenses
| Medical Oncology | |
| Hematology | |
| Internal Medicine |
Training Experience
| 2004 | Residency, University of Chicago Hospitals |
| 2007 | Fellowship, Northwestern University, McGaw Medical Center (Northwestern Memorial Hospital) |
Education/Academic qualification
MD, University of Pittsburgh
… → 2001
Research interests
- Acute Leukemias
- Anemia
- Aplastic Anemia
- Chronic Leukemias
- Leukemia
- Myelodysplastic Syndrome
- Myeloproliferative Diseases
- Targeted Therapies
Fingerprint
Dive into the research topics where Jessica K Altman is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Prot #APTO-CG-806-03: A Phase 1a/b Trial of CG-806 in Patients with Relapsed/Refractory Acute Myeloid Leukemia
1/27/21 → 1/27/24
Project: Research project
-
Acute Myeloid Leukemia, Version 2.2021 Featured Updates to the NCCN Guidelines
Pollyea, D. A., Bixby, D., Perl, A., Bhatt, V. R., Altman, J. K., Appelbaum, F. R., Lima, M. D., Fathi, A. T., Foran, J. M., Gojo, I., Hall, A. C., Jacoby, M., Lancet, J., Mannis, G., Marcucci, G., Martin, M. G., Mims, A., Neff, J., Nejati, R., Olin, R. & 14 others, , Jan 2021, In: JNCCN Journal of the National Comprehensive Cancer Network. 19, 1, p. 16-27 12 p.Research output: Contribution to journal › Article › peer-review
Open Access10 Scopus citations -
BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study
Borthakur, G., Ofran, Y., Tallman, M. S., Foran, J., Uy, G. L., DiPersio, J. F., Showel, M. M., Shimoni, A., Nagler, A., Rowe, J. M., Altman, J. K., Abraham, M., Peled, A., Shaw, S., Bohana-Kashtan, O., Sorani, E., Pereg, Y., Foley-Comer, A., Oberkovitz, G., Lustig, T. M. & 10 others, , Apr 15 2021, In: Cancer. 127, 8, p. 1246-1259 14 p.Research output: Contribution to journal › Article › peer-review
3 Scopus citations -
Clinical features and survival outcomes in patients with chronic myelomonocytic leukemia arising in the context of germline predisposition syndromes
St. Martin, E. C., Ferrer, A., Wudhikarn, K., Mangaonkar, A., Hogan, W., Tefferi, A., Gangat, N., Lasho, T., Altman, J. K., Godley, L. A. & Patnaik, M. M., Sep 1 2021, In: American Journal of Hematology. 96, 9, p. E327-E330Research output: Contribution to journal › Letter › peer-review
Open Access1 Scopus citations -
Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor (Clinical Pharmacokinetics, (2020), 59, 10, (1273-1290), 10.1007/s40262-020-00888-w)
James, A. J., Smith, C. C., Litzow, M., Perl, A. E., Altman, J. K., Shepard, D., Kadokura, T., Souda, K., Patton, M., Lu, Z., Liu, C., Moy, S., Levis, M. J. & Bahceci, E., Sep 2021, In: Clinical Pharmacokinetics. 60, 9, p. 1251 1 p.Research output: Contribution to journal › Comment/debate › peer-review
Open Access -
Inhibitory effects of Tomivosertib in acute myeloid leukemia
Suarez, M., Blyth, G. T., Mina, A. A., Kosciuczuk, E. M., Dolniak, B., Dinner, S., Altman, J. K., Eklund, E. A., Saleiro, D., Beauchamp, E. M. & Platanias, L. C., May 11 2021, In: Oncotarget. 12, 10, p. 955-966 12 p.Research output: Contribution to journal › Article › peer-review
Open Access